Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Azelon receives $4.5m to support nasal spray development
Other Azelon investors are Lighthouse Capital Partners and Covington Venture Fund. ZT-034, which comprises teriparatide (PTH1-34) is said to provide an alternative for patients at high risk of
Other Azelon investors are Lighthouse Capital Partners and Covington Venture Fund. ZT-034, which comprises teriparatide (PTH1-34) is said to provide an alternative for patients at high risk of
The new plant will manufacture both intravenous and oral solid medicines. According to the company, the new plant will help meet the rising demand for its products in
Anacor has entered into partnership and works with UCSF to discover new antimalarial agents. Anacor discovers, develops small-molecule therapeutics derived from its boron chemistry platform. In addition Anacor
Edgemont’s Fluoxetine 60 mg tablet is a single pill which is used to treat major depressive disorder, obsessive compulsive disorder in adults and pediatrics, and bulimia nervosa and
DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol. LibiGel is a testosterone gel used to treat female sexual dysfunction (FSD), specifically
Brana Vita is rich in arabinoxylan oligosaccharides (AXOS), soluble fibers derived from the cell walls of wheat bran. The AXOS are potent prebiotics which stimulates the growth of
Incivek is used for people with genotype 1 chronic hepatitis C with compensated liver disease including cirrhosis. The drug has been approved by Health Canada for use in
Astaxanthin is a natural supplement which has antioxidant activity, supports anti-inflammatory response besides improving skin, muscle and joint health. Cyanotech president and CEO Brent Bailey said the company
The ZuraLac product is a non-iodine based sanitizer targeting dairy mastitis and has been developed to prevent healthcare acquired infections in hospitals and healthcare settings. The company said
The trial comprised 121 patients who were treated with Copaxone, 101 were treated with Betaseron or Rebif (high-dose interferon) and 53 were treated with Avonex (low-dose interferon). The